These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure: The REVEAL-HF Randomized Clinical Trial. Ahmad T; Desai NR; Yamamoto Y; Biswas A; Ghazi L; Martin M; Simonov M; Dhar R; Hsiao A; Kashyap N; Allen L; Velazquez EJ; Wilson FP JAMA Cardiol; 2022 Sep; 7(9):905-912. PubMed ID: 35947362 [TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: the results from the DATA-HELP registry. Jankowska EA; Kalicinska E; Drozd M; Kurian B; Banasiak W; Ponikowski P Int J Cardiol; 2014 Oct; 176(3):852-8. PubMed ID: 25156847 [TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of generic commercial versus locally customized clinical decision support tools to reduce prescription of nonsteroidal anti-inflammatory drugs for patients with heart failure. Shakowski C; Page Ii RL; Wright G; Lunowa C; Marquez C; Suresh K; Allen LA; Glasgow RE; Lin CT; Wick A; Trinkley KE J Am Med Inform Assoc; 2023 Aug; 30(9):1516-1525. PubMed ID: 37352404 [TBL] [Abstract][Full Text] [Related]
25. Clinical Decision Support with or without Shared Decision Making to Improve Preventive Cancer Care: A Cluster-Randomized Trial. Elliott TE; Asche SE; O'Connor PJ; Dehmer SP; Ekstrom HL; Truitt AR; Chrenka EA; Harry ML; Saman DM; Allen CI; Bianco JA; Freitag LA; Sperl-Hillen JM Med Decis Making; 2022 Aug; 42(6):808-821. PubMed ID: 35209775 [TBL] [Abstract][Full Text] [Related]
27. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593 [TBL] [Abstract][Full Text] [Related]
28. Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation - Results from the German EuroAspire IV cohort. Morbach C; Wagner M; Güntner S; Malsch C; Oezkur M; Wood D; Kotseva K; Leyh R; Ertl G; Karmann W; Heuschmann PU; Störk S BMC Cardiovasc Disord; 2017 May; 17(1):108. PubMed ID: 28476146 [TBL] [Abstract][Full Text] [Related]
29. A Behavioral Economics-Electronic Health Record Module to Promote Appropriate Diabetes Management in Older Adults: Protocol for a Pragmatic Cluster Randomized Controlled Trial. Belli HM; Troxel AB; Blecker SB; Anderman J; Wong C; Martinez TR; Mann DM JMIR Res Protoc; 2021 Oct; 10(10):e28723. PubMed ID: 34704959 [TBL] [Abstract][Full Text] [Related]
30. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633 [TBL] [Abstract][Full Text] [Related]
32. A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). Karlsson LO; Nilsson S; Bång M; Nilsson L; Charitakis E; Janzon M PLoS Med; 2018 Mar; 15(3):e1002528. PubMed ID: 29534063 [TBL] [Abstract][Full Text] [Related]
33. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
34. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. Rossignol P; Duarte K; Girerd N; Karoui M; McMurray JJV; Swedberg K; van Veldhuisen DJ; Pocock S; Dickstein K; Zannad F; Pitt B Eur J Heart Fail; 2020 Aug; 22(8):1402-1411. PubMed ID: 31919958 [TBL] [Abstract][Full Text] [Related]
37. Study protocol for a type III hybrid effectiveness-implementation trial to evaluate scaling interoperable clinical decision support for patient-centered chronic pain management in primary care. Salloum RG; Bilello L; Bian J; Diiulio J; Paz LG; Gurka MJ; Gutierrez M; Hurley RW; Jones RE; Martinez-Wittinghan F; Marcial L; Masri G; McDonnell C; Militello LG; Modave F; Nguyen K; Rhodes B; Siler K; Willis D; Harle CA Implement Sci; 2022 Jul; 17(1):44. PubMed ID: 35841043 [TBL] [Abstract][Full Text] [Related]
38. Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population. Jonsson A; Norberg H; Bergdahl E; Lindmark K Cardiovasc Ther; 2018 Oct; 36(5):e12459. PubMed ID: 30019390 [TBL] [Abstract][Full Text] [Related]
39. Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF model. Burger PM; Savarese G; Tromp J; Adamson C; Jhund PS; Benson L; Hage C; Tay WT; Solomon SD; Packer M; Rossello X; McEvoy JW; De Bacquer D; Timmis A; Vardas P; Graham IM; Di Angelantonio E; Visseren FLJ; McMurray JJV; Lam CSP; Lund LH; Koudstaal S; Dorresteijn JAN; Mosterd A; Eur J Heart Fail; 2023 Nov; 25(11):1962-1975. PubMed ID: 37691140 [TBL] [Abstract][Full Text] [Related]